Skip to main content
Premium Trial:

Request an Annual Quote

Editas Medicine: Jim Mullen

Jim Mullen has been appointed as CEO of Editas Medicine, where he will replace Cindy Collins. He will take up his new post Feb. 15 and will continue to serve as chairman of the company's board of directors, a role he assumed in March 2018. Previously, Mullen was CEO and a director of Patheon, a contract development and manufacturing organization that was acquired by Thermo Fisher Scientific in 2017. Prior to that, he was president and CEO of Biogen, where he previously held various other positions, including chief operating officer, VP international, and VP of operations. He is also a member of the board of the directors of Thermo Fisher Scientific. Mullen holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.